NCT03620123View on ClinicalTrials.gov

A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 16, 2018

Primary Completion Date

June 20, 2021

Study Completion Date

June 19, 2022

Conditions
Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCarcinoma, Squamous Cell of Head and Neck
Interventions
DRUG

Nivolumab and Ipilimumab

Nivolumab 3 mg/kg of body weight intravenous infusion every two weeks and ipilimumab 1 mg/kg of body weight intravenous infusion every six weeks

DRUG

Docetaxel

docetaxel 75 mg/m² intravenous infusion every three weeks

Trial Locations (1)

45147

Essen University Hospital, Essen

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

AIO-Studien-gGmbH

OTHER

NCT03620123 - A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck | Biotech Hunter | Biotech Hunter